DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation
Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.
ChartMill8 gün önceDXCM
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Benzinga9 gün önceDXCM
The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.
SeekingAlpha10 gün önceDXCM
1 Healthcare Stock to Target This Week and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.
Yahoo15 gün önceDXCM
Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup
Dexcom (DXCM) passes strong growth & technical screens with high scores, solid fundamentals, and a bull flag breakout setup.
ChartMill15 gün önceDXCM
DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow
DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...
Yahoo17 gün önceDXCM
DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued?
DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns over the past month and past 3 months now stand out against its longer term record. See our latest analysis for DexCom. Short term momentum in DexCom has been strong, with the 30 day share price return of 17.09% and the 90 day share price return of 34.06% contrasting with a more modest 1 year total...
Yahoo18 gün önceDXCM
DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates
DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative. Stay updated...
Yahoo18 gün önceDXCM
1 Surging Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Yahoo19 gün önceDXCM
1 Growth Stock to Stash and 2 We Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Yahoo19 gün önceDXCM
1 S&P 500 Stock on Our Buy List and 2 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Yahoo20 gün önceDXCM
Is Wall Street Bullish or Bearish on DexCom Stock?
Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
Yahoo21 gün önceDXCM
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Yahoo22 gün önceDXCM
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
Yahoo22 gün önceDXCM
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
Yahoo22 gün önceDXCM
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
Yahoo22 gün önceDXCM
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
Yahoo22 gün önceDXCM
Tracking Baillie Gifford's 13F Portfolio - Q2 2026 Update
Baillie Gifford Q2 2026 13F: portfolio grew to $110B; SpaceX IPO (SPCX) tops holdings, NVDA added, AMZN trimmed. Read more analysis here.
SeekingAlpha28 gün önceDXCM
DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock
DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.
ChartMillgeçen ayDXCM